We previously showed that serum PTX3 and MUC1 soluble form, also known as CA15-3, could serve as a circulating biomarker to identify ccRCC patients with poor outcomes [12,26]. The gene discussed is PTX3; the disease is nonpapillary renal cell carcinoma.